Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAFTADINE vs BEPADIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
Hypertension,Diabetic nephropathy in patients with type 2 diabetes and hypertension,Heart failure (NYHA class II-IV) as adjunctive therapy,Stroke prevention in hypertensive patients with left ventricular hypertrophy
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes glucuronidation.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal excretion (70-80% unchanged) with minor biliary/fecal elimination (10-15%)
Approximately 40% bound to plasma proteins.
95-98% bound primarily to albumin
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
0.2-0.4 L/kg indicating moderate tissue distribution
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
Oral: 60-75%; complete with IV administration
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, reduce dose by 50% or increase dosing interval to every other day.
No dose adjustment required for any degree of hepatic impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use not recommended.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
Not approved for pediatric use.
No specific dose adjustment needed; use same dose as for younger adults.
Initiate at 2.5 mg once daily; titrate slowly due to increased sensitivity and risk of falls.
None
None
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
Fetal toxicity: Use in pregnancy can cause fetal harm; discontinue as soon as possible when pregnancy is detected,Hypotension in volume-depleted patients,Renal function deterioration in patients with bilateral renal artery stenosis or single kidney,Hyperkalemia, especially in renal impairment or concomitant use of potassium-sparing diuretics,Avoid use with aliskiren in patients with diabetes
Hypersensitivity to alcaftadine or any component of the formulation
Pregnancy (second and third trimesters),Hypersensitivity to bepadin or any component,Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min)
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
No significant food interactions reported. Grapefruit juice does not affect bepotastine metabolism. Avoid excessive alcohol intake due to potential for increased sedation.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution; may cause fetal bradycardia and hypotension.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
Not known if excreted in human milk. M/P ratio not established. Caution advised; consider risk-benefit. Monitor infant for excessive sedation and feeding difficulties.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
No standard dose adjustment recommended; however, increased renal clearance and volume of distribution may require dose increase or more frequent administration. Monitor clinical response and adjust based on therapeutic drug monitoring if available.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
BEPADIN (bepotastine besilate), a second-generation antihistamine, is indicated for allergic rhinitis and urticaria. It does not require hepatic metabolism, making it suitable for patients with liver impairment. Onset of action is within 1 hour. Avoid concurrent use with CNS depressants due to additive sedative effects.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
Take once daily in the morning or as directed by your physician.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol consumption as it can intensify drowsiness.,Report any severe allergic reactions, such as difficulty breathing or swelling, to your healthcare provider immediately.,Store at room temperature away from moisture and heat.
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAFTADINE vs BEPADIN, answered by our medical review team.
ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. BEPADIN is a Ophthalmic Antihistamine that works by Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAFTADINE and BEPADIN depend on the specific clinical indication. These are both Ophthalmic Antihistamine agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. The standard adult dose of BEPADIN is: 5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAFTADINE and BEPADIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. BEPADIN is classified as Category C. Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.